Nimotuzumab

尼妥珠单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameNimotuzumab
Drug Alias NameAnti-EGFR mAb hR3尼莫妥珠单抗重组人源化单克隆抗体h-R3VECTHIXNituzumab +[20] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Gastroesophageal Junction NeoplasmsSolid tumours +[20] 
Global Approved IndicationsNasopharyngeal NeoplasmsHead and Neck Neoplasms
Approved Indications in ChinaNasopharyngeal Neoplasms
Original Approved Country/TerritoryIndia
Original Approved Date2006/07/21
Country/TerritoryCanadaUnited StatesSingapore +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCenter Of Molecular ImmunologyCimym Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Beijing UniversityBiotech Pharmaceutical Co LtdInnogene Kalbiotech Pte. Ltd +[10] 
Inactive CompaniesYM BioSciences IncPeking UniversityCimym Biosciences +[4] 
Active IndicationsPancreatic neuroendocrine tumors (pNET)Gastroesophageal Junction NeoplasmsNasopharyngeal Diseases +[15] 
Inactive IndicationsSolid tumoursEsophageal DiseasesCarcinoma, Non-Small-Cell Lung +[5] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBank